EP0948642A1 - Procede de detection de cellules de champignons resistantes dans un materiau clinique - Google Patents

Procede de detection de cellules de champignons resistantes dans un materiau clinique

Info

Publication number
EP0948642A1
EP0948642A1 EP97909359A EP97909359A EP0948642A1 EP 0948642 A1 EP0948642 A1 EP 0948642A1 EP 97909359 A EP97909359 A EP 97909359A EP 97909359 A EP97909359 A EP 97909359A EP 0948642 A1 EP0948642 A1 EP 0948642A1
Authority
EP
European Patent Office
Prior art keywords
seq
hybridization
nucleotide sequences
hybridization probes
fungal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97909359A
Other languages
German (de)
English (en)
Inventor
Hermann Einsele
Jürgen LÖFFLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eberhard Karls Universitaet Tuebingen
Universitaetsklinikum Tuebingen
Original Assignee
Eberhard Karls Universitaet Tuebingen
Universitaetsklinikum Tuebingen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19643486A external-priority patent/DE19643486C1/de
Application filed by Eberhard Karls Universitaet Tuebingen, Universitaetsklinikum Tuebingen filed Critical Eberhard Karls Universitaet Tuebingen
Publication of EP0948642A1 publication Critical patent/EP0948642A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • the present invention relates to a method for the detection of resistant fungal cells in clinical material.
  • the general interest in methods for the detection of fungal cells can be seen against the background that fungal species in particular as nosocomial pathogens have gained considerable importance in immunosuppressed patients, in particular in recent years.
  • the previously known methods for the analysis of fungal infections primarily aim to enable a diagnosis of the fungal infection and an identification of the pathogenic fungal species. To do this, one uses, for example, a cultivation of fungal species from clinical material on suitable nutrient media and, if necessary, molecular biological methods.
  • the genus Candida which belongs to the fungi imperfecti, is one of the medically most important facultative pathogenic fungal genera. It causes the so-called candida mycoses, also called candida.
  • candida mycoses also called candida.
  • the most important pathogen within the genus Candida is the species Candida albicans, which in addition to the mostly less serious infections of the skin and mucous membranes also causes deep organ mycoses or system mycoses.
  • Systemic mycoses are fungal infections that affect not only the skin or mucous membranes, but also other organs, organ systems or even the whole organism. In the latter case one speaks of "generalized" fungal infections.
  • Candida albicans infections can be diagnosed is in the publication "Detection of surgical pathogens by in vitro DNA amplification. Part I. Rapid identification of Candida albicans by in vitro amplification of a fungus pecific gene" by Buchman et al. (1990), Surgery 108, pages 338 to 347.
  • a Candida albicans infection is detected by PCR aplification of another fungal-specific gene area, namely the gene for the enzyme 14-oj-lanosterol demethylase.
  • PCR products are not detected here by hybridization, but by separation in the agarose gel and staining of the DNA with ethidium bromide.
  • molecular biological techniques are used to detect fungal infections in patient material and, as in the Niesters publication to additionally distinguish different species of the genus Candida.
  • azole derivatives the polyene amphotericin B, flucytosine, griseofulvin and terbinafine.
  • antifungals commonly used are the azole derivatives, which include, for example, the fluconazole.
  • azole derivatives are initially given as the "agent of choice", but it can only be concluded that the patient is not infected with azole derivative-resistant fungal cells despite the fact that there is no improvement despite high doses and long-term treatment. This diagnosis is often only made when the course of infection in the patient takes a dramatic course despite treatment with the azole derivatives, which are ineffective here.
  • this object is achieved by a method with the following steps:
  • fungus-specific nucleic acids can preferably be extracted from blood, but also from biopsy material, sputum, mucosal smears or other patient material. Either the fungus-specific DNA or RNA can be isolated, which can then be detected by DNA / DNA, DNA / RNA or RNA / RNA hybridization.
  • hybridization probes used being radioactive or non-radioactive labeled and then the specific hybridization being detected by autoradiography or enzyme-catalyzed color reactions.
  • the hybridization probes are directed against a DNA segment from the 14- ⁇ -lanosterol demethylase gene.
  • the inventors of the present application were able to show that, in the case of fungal species which have resistance to azole derivatives, mutations occur in this gene region of the fungal DNA, which surprisingly correlate highly significantly with the clinical and microbiological finding of an azole derivative resistance.
  • Ergosterol is a steroid that is stored in the so-called plasmalemma, the phospholipid layer that adheres to the inside of the cell wall of the fungi.
  • Ergosterol is synthesized in the cell from lanosterol, a precursor.
  • the decisive step in the synthesis of ergosterol from lanosterol is catalyzed by the enzyme 14- ⁇ t-lanosterol demethylase, or 14-DM for short. Since ergosterol is an essential component of the plasma membrane, cell division can no longer take place in the absence of ergosterol. A new synthesis of cell wall and plasma membrane is always necessary for cell division.
  • the inhibition of ergosterol synthesis which is essential for the growth of the fungal cells, can be successfully used to combat fungal infections.
  • hybridization probes are used against the gene which codes for the protein on which the azole derivatives attack directly.
  • changes in the nucleic acid sequence occur frequently in this gene.
  • the specific hybridization probes are then designed in such a way that they recognize these sequence changes, that is to say only bind to gene sections of fungal cells which have resistance to azole derivatives.
  • the hybridization probes are directed against a DNA segment from the 14- ⁇ -lanosterol demethylase gene of the species Candida albicans. This gene is also called ERG16 gene in Candida albicans.
  • the advantage here is that the hybridization probes make it possible to diagnose resistant strains of the most widespread pathogenic fungal species, namely Candida albicans.
  • a PCR reaction is carried out between steps a) and b), in which sections of the 14-cu-lanosterol demethylase gene are amplified.
  • This measure therefore has the advantage that the method gains both sensitivity and specificity, since large quantities of starting material are generated, in which only the required gene segment is specifically contained.
  • the material amplified with PCR is then used, for example, in Southern hybridization.
  • nucleotide sequences SEQ ID-No: 1 and SEQ ID-No: 2 or the nucleotide sequences SEQ ID-No: 3 and SEQ ID-No: 4 are used as primer pairs in the PCR reaction become.
  • these primer pairs are used to amplify DNA sections which contain DNA sequences characteristic of resistant fungus species.
  • the resulting amplification products are significantly shorter than the entire gene and thus enable easier processing.
  • nucleotide sequences SEQ ID-No: 5 to 8 of the enclosed sequence protocol are used as hybridization probes in step b).
  • the inventors of the present application have recognized that surprisingly resistant Candida species, the resistance of which has only come about through a single base exchange in the ERG16 gene, can be distinguished from sensitive strains which do not have this mutation using these hybridization probes.
  • the hybridization probes are marked with digoxigenin in step b) and used in the Southern hybridization. Specific hybridization is then detected using enzyme-conjugated anti-digoxigenin antibodies, the enzymes catalyzing color reactions.
  • the advantage here is that the labeling of the hybridization probes does not have to be radioactive.
  • large amounts of hybridization probes can be labeled at the same time, which can then be aliquoted and stored at -20 ° C because they are stable over a long period of time. Aliquots from the same labeling reaction can then be thawed and used for the individual detection reactions, so that high reproducibility is ensured over long periods of time.
  • radioactive labeling methods and other non-radioactive labeling methods, such as labeling with biotin, are also possible.
  • nucleic acid to be analyzed can be quickly applied to a membrane, for example a microcellulose or nylon membrane.
  • a membrane for example a microcellulose or nylon membrane.
  • the fastest method is the "blot-blot” or “dot-blot” method familiar to the person skilled in the art.
  • the fungal DNA can be used directly or previously amplified by PCR in the Southern hybridization. However, it is understood that it is also possible to analyze fungal specific RNAs. These can either be isolated directly from the cytoplasm of fungal cells, or can only be produced by reverse transcription. The analysis can then be carried out by Northern blot or further RNA detection reactions.
  • the hybridization does not have to be carried out on membranes, such as, for example, in Southern or Northern hybridization, but can also be carried out in solution or on columns.
  • step b If the hybridization probes with the nucleic acid sequences SEQ ID-No: 4 to 8 are used in step b), it is preferred if after the hybridization a washing step is carried out at a temperature which is about 1 ° C. below that Melting temperature (Tm) of the hybridization probe used in each case.
  • Tm Melting temperature
  • the invention further relates to the nucleotide sequences SEQ ID-No: 1 to 8 from the enclosed sequence listing. It is preferred if the nucleotide sequences SEQ ID-No: 1 and 2 are used as primers for the PCR reaction and the nucleotide sequences SEQ ID-No: 5 and / or 6 as hybridization probes in the method for the detection of azole derivative-resistant fungal cells .
  • nucleotide sequences SEQ ID-No: 3 and 4 are used as primers and the nucleotide sequences SEQ ID-No: 7 or 8 as hybridization probes in the method according to the invention.
  • This measure has the advantage that, in this way, initially easily amplifiable, easy-to-handle DNA fragments of 300-400 base pairs are provided in large quantities in the PCR, and then the base exchanges which may be contained in these PCR fragments with the Hybridization probes can be identified.
  • the inventors of the present application were able to show that a number of individual base exchanges occur in azole derivative-resistant fungal strains with respect to the azole derivative-sensitive fungal strains.
  • a base exchange from T to G in the ERG16 gene leads to the amino acid phenylalanine No. 105 of the enzyme 14-DM being mutated to a leucine.
  • This T / G exchange can be detected at the gene level using the hybridization probe with the nucleotide sequence SEQ ID-No: 5.
  • the inventors have recognized that a base exchange from A to C can occur in resistant fungal strains, whereby the amino acid glutamine No. 142 is mutated to a proline.
  • This mutation can be detected using the hybridization probe with the nucleotide sequence SEQ ID-No: 6.
  • These two point mutations are detected with the hybridization probes with the nucleotide sequences SEQ ID-No: 7 and 8, respectively.
  • resistant fungal strains on the specifically amplified PCR fragment either contain one or more of the base changes, it is advantageous if the corresponding hybridization probes are used simultaneously in the Southern hybridization. With a positive signal, there is in any case a resistant fungus species. If only one of the hybridization probes is used for hybridization, it can be demonstrated which mutation has occurred in this resistant fungal strain and whether one or more mutations are present.
  • nucleotide sequences SEQ ID-No: 1 and SEQ ID-No: 4 can also be combined as primers, so that then on the amplified PCR fragment of approximately 1,400 base pairs all with the hybridization probes with the nucleotide sequences SEQ ID-No: 5 to 8 detectable mutations are included.
  • the invention further relates to a kit for analyzing fungal infections with azole derivative-resistant fungal strains, one or more of the nucleotide sequences SEQ ID-No: 1 to 8 being contained in this kit.
  • the kit contains all the solutions required to carry out the PCR reaction and hybridization be included. This makes it possible to have the method according to the invention carried out in a routine laboratory by trained personnel. In addition, the process can be carried out quickly and without lengthy preparations with high reproducibility if all the substances required for many reactions are provided in the kit.
  • Candida albicans strains For the analysis and comparison of resistant Candida albicans strains with sensitive Candida albicans strains, patient material or yeast samples are incubated for 48 hours at 30 ° C on a medium used for yeast cultivation, the Sabouraud glucose agar. Then several colonies are inoculated and taken up in sterile 0.9% sodium chloride solution.
  • the fungal cells are disrupted by alkaline lysis (50 mM NaOH, 10 minutes, 95 ° C.) and then neutralization and enzymatic treatment with zymolyase from Sigma.
  • the proteins are denatured in Tris / EDTA and 10% SDS solution at 65 ° C.
  • the now available solution contains debris from the fungal cells and free fungal DNA, which must now be isolated.
  • a protein precipitation with 5 M potassium acetate is carried out and the DNA is precipitated by adding ice-cold isopropanol.
  • the precipitation product is used for the further process steps.
  • Example 3 Amplification of a DNA fragment from the
  • the PCR reaction first serves to amplify sections from the ERG16 gene to which the specific hybridization probes bind.
  • the ERG16 gene which is 1851 bp long, is divided into sections that are easy to handle and that can be easily amplified in PCR.
  • DNA sequence SEQ ID-No: 5 and / or 6 is to be used as the hybridization probe, a PCR with primers with the nucleotide sequences SEQ ID-No: 1 (upstream primer) and 2 (downstream primer) is carried out.
  • a PCR product is then obtained with the primers mentioned, which comprises the range from base 379 to base 676, that is to say approximately 300 base pairs of the ERG16 gene.
  • the PCR primers with the nucleotide sequences SEQ ID-No: 3 (upstream primer) and 4 (downstream primer) are used.
  • the PCR conditions are as follows:
  • Terminal extension 5 min at 72 ° C
  • the high magnesium concentration in the buffer ensures a high specificity of the polymerase, which can work at 72 ° C in the extension step at its optimum temperature.
  • the PCR reactions result in a sufficient quantity of starting material to be used to further analyze whether the DNA comes from resistant or sensitive fungal cells.
  • the PCR products obtained in Example 3 are heat-denatured and applied to nylon membranes, for example in the slo-blot process familiar to the person skilled in the art.
  • the DNA is cross-linked on the nylon membrane.
  • the hybridization probes are labeled by incorporating digoxigenin-labeled nucleotides into methods which are known to the person skilled in the art (for example “nick translation” or random priming ”).
  • the membrane is prehybridized for 20 minutes in 6 x SSPE, 5 x Denharts solution, 0.1% N-lauryl-sarcosine-Na, 0.02% SDS at 42 ° C.
  • hybridization is then carried out in the prehybridization solution described above, to which 30 pM digoxigenized hybridization probe has been added, for 20 minutes at 42 ° C.
  • 30 pM digoxigenized hybridization probe has been added, for 20 minutes at 42 ° C.
  • the specificity of the hybridization is determined by washing steps which then take place.
  • the first two washing steps are carried out for 5 minutes in 2 x SSPE, 0.1% SDS at 42 ° C.
  • two washing steps are carried out for 7 minutes each in 6 x SSPE, 1% SDS, the washing temperature being approximately, preferably exactly 1 ° C. below the Tm value.
  • the melting temperatures of the hybridization probes and the base changes detectable by the hybridization probes are given in Table I. If the nucleotide sequence of the hybridization probe does not exactly match the corresponding sequence of the PCR fragment, the hybridization probe is washed away in this step.
  • the detection reaction is then carried out, in which it is examined whether digoxigenized hybridization probe is present on the membrane or not. This is done in a process according to the manufacturer's protocol of Boehringer Mannheim with the aid of enzyme-conjugated anti-digoxigenin antibodies. The enzyme then catalyzes a reaction that leads to the production of an insoluble color complex.
  • the patient contains fungal cells which are resistant to azole derivatives.
  • therapy with azole derivative antifungals is therefore pointless and the therapy for combating the Candida infection must be changed.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé pour détecter des cellules de champignons résistantes dans un matériau clinique, selon lequel on commence par extraire du matériau clinique les acides nucléiques spécifiques aux champignons puis on procède à leur hybridation avec des sondes d'hybridation spécifiques aux champignons et dirigées contre les segments d'acides nucléiques prélevés sur les cellules de champignons résistantes au dérivé d'azole.
EP97909359A 1996-10-22 1997-10-04 Procede de detection de cellules de champignons resistantes dans un materiau clinique Withdrawn EP0948642A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19643486 1996-10-22
DE19643486A DE19643486C1 (de) 1996-10-22 1996-10-22 Nachweis von resistenten Pilzzellen in klinischem Material
PCT/EP1997/005454 WO1998017825A1 (fr) 1996-10-22 1997-10-04 Procede de detection de cellules de champignons resistantes dans un materiau clinique

Publications (1)

Publication Number Publication Date
EP0948642A1 true EP0948642A1 (fr) 1999-10-13

Family

ID=7809396

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97909359A Withdrawn EP0948642A1 (fr) 1996-10-22 1997-10-04 Procede de detection de cellules de champignons resistantes dans un materiau clinique

Country Status (6)

Country Link
EP (1) EP0948642A1 (fr)
JP (1) JP3447302B2 (fr)
AU (1) AU731424B2 (fr)
CA (1) CA2268791A1 (fr)
DE (1) DE19654946A1 (fr)
WO (1) WO1998017825A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004089046A (ja) * 2002-08-30 2004-03-25 Fuso Pharmaceutical Industries Ltd カンジダアルビカンス菌の検出用プローブおよびそれを用いた方法
JP5356819B2 (ja) * 2005-09-20 2013-12-04 アドヴァンディーエックス，インコーポレイテッド 真菌類の分類および抗菌治療のための試薬、方法およびキット
US20110229902A1 (en) * 2008-10-10 2011-09-22 Stichting Ter Bevordering Van De Farmacodynamiek Method for determining the resistance status of fungi and yeasts, in particular of aspergillus fumigatus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU649734B2 (en) * 1990-08-16 1994-06-02 Isis Pharmaceuticals, Inc. Inhibition of candida
US5426026A (en) * 1993-09-15 1995-06-20 University Of Pittsburgh PCR identification of four medically important candida species using one primer pair and four species-specific probes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9817825A1 *

Also Published As

Publication number Publication date
WO1998017825A1 (fr) 1998-04-30
DE19654946A1 (de) 1998-05-07
CA2268791A1 (fr) 1998-04-30
JP3447302B2 (ja) 2003-09-16
JP2000516100A (ja) 2000-12-05
AU731424B2 (en) 2001-03-29
AU4707497A (en) 1998-05-15

Similar Documents

Publication Publication Date Title
DE3486467T3 (de) Verfahren zum Nachweis, Identifizieren und Quantifizieren von Organismen und Viren
EP0745139B1 (fr) Procede de preparation et d'hybridation de sondes specifiques
DE102007041864A1 (de) Verfahren zum Nachweis von Bakterien und Pilzen
DE3688985T2 (de) Verfahren und Sonde zum Nachweis von Actinobacillus Actinomycetemcomitans.
EP0846186B1 (fr) Extraction, amplification et hybridation sequentielle d'adn de cellules de champignons et procede de detection de cellules de champignons dans un materiau clinique
DE69032778T2 (de) Verfahren zur Untersuchung von durch Mikroorganismen verursachten Lebensmittelvergiftungen und Reagens dafür
DE69121975T2 (de) Spezifischer Nachweis von Mycobacterium Tuberculosis
DE19530333C2 (de) Amplifikation von Pilzzellen-DNA sowie Verfahren zum Nachweisen von Pilzzellen in klinischem Material
EP0595167A1 (fr) Sonde génétique spécifique et méthode de diagnostic de Candia albicans
DE69711073T2 (de) Verfahren zur erkennung von lebenden mikrobiologischen verunreinigungen in einer lebensmittelprobe
DE19635347C1 (de) Sequentielle Hybridisierung von Pilzzellen-DNA sowie Verfahren zum Nachweisen von Pilzzellen in klinischem Material
EP0948642A1 (fr) Procede de detection de cellules de champignons resistantes dans un materiau clinique
EP1232286B1 (fr) Test pour micro-organismes pour le diagnostic de sepsis
DE19643486C1 (de) Nachweis von resistenten Pilzzellen in klinischem Material
DE10053821A1 (de) Detektion von seltenen Candida-Spezies
DE69304536T2 (de) Nukleotidische sequentien von genen die für pectate-liasen kodieren und dessen verwendung für den nachweis von bakterien der gattung erwinia
DE19530336C2 (de) Sequentielle Hybridisierung von Pilzzellen-DNA sowie Verfahren zum Nachweisen und Identifizieren von Pilzzellen in klinischem Material
EP2471955B1 (fr) Molécule d'acide nucléique hybridisable spécifique à l'organisme
DE19530332C2 (de) Extraktion von Pilzzellen-DNA sowie Verfahren zum Nachweisen von Pilzzellen in klinischem Material
DE69405005T2 (de) Sonde und verfahren zum nachweis von hefen der art candida krusei
EP0871769B1 (fr) Procede permettant de reduire la formation d'artefacts lors de la transcription d'acides ribonucleiques en acides desoxyribonucleiques
WO1998032862A2 (fr) L-alanine deshydrogenase de mycobacterium marinum
US20020098483A1 (en) Method for detecting resistant fungal cells in clinical material
WO1998032862A9 (fr) L-alanine deshydrogenase de mycobacterium marinum
EP2877595B1 (fr) Procédé de différenciation entre cellules vivantes et mortes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990403

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FI FR GB IT LI NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20030812